Half life hazard course skin#

Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. Overgrowth of non-susceptible microorganismsĪs with other antibiotics, use of cefuroxime axetil may result in the overgrowth of Candida. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease (see section 4.8). It results directly from the bactericidal activity of cefuroxime axetil on the causative bacteria of Lyme disease, the spirochaete Borrelia burgdorferi. The Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated.īefore beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactam antibiotics because there is a risk of cross-sensitivity. Recommended doses for Cefuroxime axetil in renal impairment Cefuroxime is effectively removed by dialysis. In patients with markedly impaired renal function it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion. The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established.Ĭefuroxime is primarily excreted by the kidneys. There is no experience of using Cefuroxime axetil in children under the age of 3 months.

Half life hazard course skin#

Uncomplicated skin and soft tissue infectionsġ5 mg/kg twice daily to a maximum of 250 mg twice daily for 14 days (10 to 21 days) Date of first authorisation/renewal of the authorisationĪcute tonsillitis and pharyngitis, acute bacterial sinusitisġ0 mg/kg twice daily to a maximum of 125 mg twice dailyĬhildren aged two years or older with otitis media or, where appropriate, with more severe infectionsġ5 mg/kg twice daily to a maximum of 250 mg twice dailyġ5 mg/kg twice daily to a maximum of 250 mg twice daily for 10 to 14 days

6.6 Special precautions for disposal and other handling.

4.7 Effects on ability to drive and use machines.

4.5 Interaction with other medicinal products and other forms of interaction.

4.4 Special warnings and precautions for use.

4.2 Posology and method of administration.

Show table of contents Hide table of contents